Aktie A0M84G KAROLINSKA DEVELOPMENT AB
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Karolinska Development AB

Aktien

A0M84G

SE0002190926

KDEV

Markt geschlossen - Nasdaq Stockholm
Andere Börsenplätze
 17:29:39 03.06.2024 		% 5 Tage % 1. Jan.
1,54 SEK +1,32 % Intraday Chart für Karolinska Development AB +2,39 % -9,31 %
28.05. Karolinska Development strebt 10%-Beteiligung an Boost Pharma an MT
16.05. Karolinska Development AB (Publ) ernennt Hans Wigzell zum Direktor und zum Vorsitzenden CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Karolinska Development Targets 10% Stake in Boost Pharma
Karolinska Development AB Appoints Hans Wigzell as Director and as Chairman
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election
Karolinska Development AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Karolinska Development Portfolio Company AnaCardio Completes SEK150 Million Funding Round
Karolinska Development Takes Part in Portfolio Company Umecrine Cognition's Capital Raise
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Modus Therapeutics to Launch SEK40 Million Rights Offering, Issue Shares to Offset SEK20 Million Loan
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery
Karolinska Development AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Karolinska Unit's Investigational Drug Shows Potential as Anemia Treatment
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2023
Karolinska Development's Portfolio Company Biosergen Presents Positive Results from Phase 1 Study of Drug Candidate to Treat Systemic Fungal Infection
Karolinska Development AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Karolinska Development AB Reports Earnings Results for the Full Year Ended December 31, 2022
Karolinska Development AB Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data
Karolinska Development Up 9% as Umecrine Wins US Orphan Drug Tag for Liver Disease Drug Candidate
Karolinska Development AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Karolinska Development Partakes In Danish Dermatology Company Henlez' Seed Financing
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0M84G Aktie
  4. Nachrichten Karolinska Development AB
  5. Andere Sprachen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT